Everything You Need to Know About NexCAR19™ CAR-T Therapy for Cancer Treatment
Published: Mar 24, 2026
Updated: May 20, 2026
Published: Mar 24, 2026
Updated: May 20, 2026
Cancer care is undergoing a profound transformation. Treatments that once relied solely on surgery, chemotherapy, and radiation are now being complemented and, in some cases, surpassed by advanced immunotherapies that harness the power of the human immune system. Among these innovations, CAR-T cell therapy stands out as one of the most revolutionary approaches in modern oncology.
India has made a historic entry into this space with NexCAR19, the country's first indigenously developed CAR-T cell therapy. NexCAR19 is not just a scientific milestone; it represents hope for patients with aggressive blood cancers who have limited treatment options.
CAR-T cell therapy, short for Chimeric Antigen Receptor T-cell therapy, is a form of personalised immunotherapy. Unlike traditional cancer treatments that directly target tumours, CAR-T therapy empowers a patient's own immune system to recognise and destroy cancer cells.
In simple terms, the therapy involves:
Globally, CAR-T therapies have shown remarkable success, particularly in patients whose cancer has relapsed or not responded to chemotherapy, targeted therapy, or even bone marrow transplantation.
NexCAR19 is India's first approved CD19-directed CAR-T cell therapy. It is designed to treat specific B-cell malignancies, which are cancers that arise from B-lymphocytes, a type of white blood cell.
What makes NexCAR19 truly significant is that it is developed and manufactured in India, through a collaboration between ImmunoACT and Tata Memorial Centre. This collaboration combined advanced biotechnology expertise with one of India's most respected cancer institutions, resulting in a therapy tailored for Indian patients while meeting global scientific standards.
Approved in 2023, NexCAR19 marked a turning point by making advanced immunotherapy more accessible and affordable in India.
Although NexCAR19 is based on highly advanced science, the treatment journey can be understood in a step-wise manner:
1. Patient Evaluation and Eligibility
Not every cancer patient is immediately eligible for CAR-T therapy. Doctors carefully evaluate:
NexCAR19 is primarily recommended for patients with relapsed or refractory disease, meaning the cancer has returned or failed to respond to standard treatments.
2. T-Cell Collection (Leukapheresis)
Once approved, the patient undergoes leukapheresis. Blood is drawn, and T-cells are separated and collected. This process is usually painless and similar to blood donation.
3. Genetic Engineering of T-Cells
The collected T-cells are sent to a specialised laboratory, where they are genetically modified to express a chimeric antigen receptor (CAR) that targets the CD19 protein present on cancerous B-cells.
4. Expansion and Quality Testing
The modified CAR-T cells are multiplied to produce millions of potent cancer-fighting cells. These cells undergo rigorous quality and safety checks before being approved for infusion.
Before the CAR-T cells are infused, patients typically receive low-dose chemotherapy to prepare the body and create space for the new cells to expand and function effectively.
The NexCAR19 cells are infused back into the patient through an intravenous line. This is usually a one-time infusion.
After infusion, patients are closely monitored for side effects and response to therapy. Most side effects, if they occur, appear within the first few weeks and are manageable in experienced centres.
Start Your NexCAR19 CAR-T Therapy Journey Connect with experienced CAR-T specialists for eligibility evaluation and personalized care support.
NexCAR19 is currently approved in India for:
These are aggressive blood cancers that often become resistant to standard treatments. For such patients, NexCAR19 offers a potentially life-saving option when alternatives are limited.
Ongoing research may expand its use to additional indications in the future.
Clinical evidence strongly supports the effectiveness of NexCAR19, particularly in patients with advanced, relapsed, or refractory B-cell cancers who have limited treatment options. Pivotal clinical trials conducted at Tata Memorial Centre, one of India's leading oncology institutions, have demonstrated both meaningful efficacy and a favourable safety profile.
In these trials, 64 patients with advanced lymphoma or leukaemia were treated with NexCAR19. The results were highly encouraging:
Equally important was the therapy's improved safety profile. Compared to other commercially available CD19-directed CAR-T therapies, NexCAR19 demonstrated:
This combination of strong anti-cancer activity and reduced treatment-related toxicity represents a significant advancement in CAR-T therapy. It not only improves clinical outcomes but also enhances patient safety and tolerability, making NexCAR19 a compelling and patient-centred option in the evolving landscape of cancer immunotherapy.
Like all CAR-T therapies, NexCAR19 can cause side effects, the most notable being:
The good news is that these side effects are well understood and manageable when treatment is delivered at experienced centres with trained oncology teams.
NexCAR19 represents far more than a new drug. It is a symbol of India's growing leadership in advanced healthcare innovation.
Key reasons why NexCAR19 is a landmark development include:
NexCAR19 is currently offered at select, highly specialised cancer centres across India. In addition to major government institutions, private healthcare providers have also entered this space.
Notably, Apollo Hospitals became the first private hospital in India to successfully administer CAR-T cell therapy and has since launched a Made-in-India CAR-T program, expanding access to this advanced treatment.
Availability is gradually increasing as more centres build the required expertise and infrastructure.
One of the most important aspects of NexCAR19 is affordability. International CAR-T therapies can be very expensive, placing them out of reach for most patients.
NexCAR19 is priced significantly lower, making CAR-T therapy a realistic option for many more families. While the exact cost varies by hospital, condition, and supportive care needs, it remains among the most affordable CAR-T options globally.
NexCAR19 has positioned India as a serious destination for advanced cancer immunotherapy. International patients are increasingly exploring India for CAR-T treatment because of:
As a result, NexCAR19 is contributing to the growth of oncology medical tourism.
Patients, both domestic and international, can access NexCAR19 CAR-T therapy through MediGence, a trusted healthcare facilitator.
Through MediGence, patients receive:
For international patients, MediGence simplifies the entire journey, ensuring clear, confident access to this advanced therapy.
The success of NexCAR19 is only the beginning. Ongoing research, expanding infrastructure, and increased clinical experience are expected to:
For patients and families facing aggressive blood cancers, this progress represents renewed hope.
NexCAR19 CAR-T therapy represents a new chapter in cancer treatmentone defined by innovation, accessibility, and patient-centred care. By combining advanced science with affordability, India has taken a decisive step toward making world-class cancer treatment available to those who need it most. With support from MediGence, patients can now navigate this complex but promising therapy with confidence, guided every step of the way.
NexCAR19 is India's first indigenously developed CAR-T cell therapy that uses a patient's own immune cells to target and destroy cancer cells. Unlike chemotherapy or radiation, which directly attack cancer, NexCAR19 reprograms T-cells to specifically recognise and eliminate cancer, making it a more targeted and personalised treatment.
NexCAR19 is primarily recommended for patients with relapsed or refractory B-cell cancers, such as B-cell Acute Lymphoblastic Leukaemia (B-ALL) and certain Non-Hodgkin Lymphomas. Eligibility depends on factors like prior treatments, overall health, and disease progression, which are evaluated by a specialist.
Clinical trials have shown promising outcomes, with around 67% of patients responding to treatment and nearly 50% achieving complete remission. These results are especially significant for patients who did not respond to previous therapies. The overall success rate falls between 70% and 75%.
Common side effects include Cytokine Release Syndrome (CRS), which may cause fever and fatigue, as well as mild neurological symptoms such as confusion or headaches. However, NexCAR19 has shown a lower risk of severe side effects than many global CAR-T therapies, and these side effects are manageable in specialised centres.
NexCAR19 is significantly more affordable than international CAR-T therapies. While costs may vary by hospital and patient condition, it is considered one of the most cost-effective CAR-T options globally, making advanced cancer care more accessible in India.
Alvina Hasan is a dedicated medical researcher and scientific writer with a strong foundation in the pharmaceutical sciences. She holds a B.Pharm from Jamia Hamdard University and an M.Pharm in Quality Assurance from DIPSAR University. With deep medical expertise and a strong interest in healthcare communication, she focuses on transforming complex clinical and scientific information into clear, engaging, and easy-to-understand narratives. She develops insightful healthcare articles and research-driven pieces designed to support both medical professionals and patients, helping bridge the gap between advanced medical knowledge and practical understanding.
Dr. Vishwas Kaushik, an accomplished Belgorod State University graduate with an MBBS, is known for his impactful contributions to healthcare. Driven by a passion for global well-being, he seamlessly led domestic operations at VMV Group of Companies and orchestrated success at Clear Medi Cancer Centre. His adept team management and operational skills have positioned him as a luminary in healthcare tourism, shaping a future where compassionate, world-class medical care knows no boundaries.
Delhi, India
Istanbul, Turkey
Istanbul, Turkey
Istanbul, Turkey
Active
.png)
